Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023
Methodological detailsbreakout sessions in five disease-specific groups
- Breakout sessions in five disease-specific groups
Recommendations
As issued by the authors
Across all disease states: continued need for clinical trial design innovation with regard to therapeutics, endpoint and disease endotypes
Rheumatoid arthritis (RA): molecular classification of disease pathogenesis and activity, pre-/early RA strategies, more refined pain profiling and innovative trial designs to deliver on precision medicine
Psoriatic arthritis (PsA): genetic, immunophenotypic, clinical signatures predicting PsA development in psoriasis; evaluation of combination therapies for difficult-to-treat disease
axSpA: role of IL-23 in pathogenesis and genetic relationship of the IL-23-receptor polymorphism with related systemic inflammatory diseases (eg, inflammatory bowel disease)
Osteoarthritis (OA): ability to reliably phenotype and stratify patients for inclusion in clinical trials
Systemic lupus erythematosus (SLE): trial endpoints reflecting pharmacodynamic/functional outcomes (eg, inhibition of type I interferon pathway activation; changes in urine biomarkers)
Systemic sclerosis (SSc) and vasculitis: lack of biomarkers that predict response or disease progression and allow stratification for therapies
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →